Here are two more of my reviews of the 10 ten abstracts from ASCO 2019:
Surviving CLL is only part of the story if we are going to succumb to second cancers. This ASCO abstract studies second cancers in CLL patients on ibrutinib or acalabrutib.
Brian - A very big Thank You from all us CLL patients for your tireless efforts to disseminate all this info from ASH. We all reap countless benefits from all your labors on our behalf. Be Well - Captain cujoe
Brian, in the second cancer study, was there any comparison between those that had previous treatments and those than had the BTK inhibitors as their only treatment? Seems that would be important to look at.
I so appreciate your work. For me, you have a way of presenting the research information in an accessible manner. Because many CLL patients live for a long time with their cancer, the landscape of treatment evolves. For those of us without a medical background, keeping current with the options is important. Thank you!
I think I have a specialist for just about every organ system. It amazes me that most if not all of them are either unaware of the increased risk of secondary neoplasms among CLL patients or minimize the significance. At least they are willing to continue to survey my “parts” in their area at my request.
I look forward to seeing Dr. Byrd next time (Sept) and will ask if thinks it is reasonable to test my CD4/CD8 ratio. When I first spoke to Dr. Byrd about Acalabrutinib he said he thought it wasn’t as effective at preserving or improving partial immune function. This time (four months ago) he was getting excited about Acalabrutinib.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
